Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
Ultragenyx Pharmaceutical (RARE) released its second quarter 2026 results on 4 August, reporting revenue of US$214 million and a net loss of US$92 million. Investors are now assessing what this means for the stock.
See our latest analysis for Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical shares trade at US$25.91 after a 4.01% 7 day share price return, although the 30 day share price return is down 25.27%. Over the past year, total shareholder return has declined 5.92%, reflecting mixed sentiment around the earnings report and the company’s progress on its rare disease portfolio.
If you are reassessing risk and reward after Ultragenyx Pharmaceutical’s latest results, it can help to widen the lens and look at other opportunities through the 43 healthcare AI stocks
Bulls point to Ultragenyx Pharmaceutical’s growing rare disease portfolio. Bears focus on ongoing losses and the sharp 30 day share price decline. The key question is whether the current valuation reflects more of the upside story or the risks ahead.
Most Popular Narrative: 30% Undervalued
Ultragenyx Pharmaceutical’s most followed narrative sets a fair value of $26.00 compared with the latest close at $25.91. The gap is small, but the story behind it is detailed.
The “Ultragenyx Turnaround Thesis” is trapped in a commercial illusion, mistaking a multi-product portfolio for financial stability while ignoring deep-rooted structural inefficiencies.
Here is why the market is mispricing the friction inside RARE’s operational engine:
Want to know what underpins that fair value for Ultragenyx Pharmaceutical? The narrative relies on a specific revenue growth path and a projected profit profile that assumes a sharp shift from current losses. Curious which margin assumptions and long term earnings multiple sit at the core of that calculation?
Result: Fair Value of $26.0 (ABOUT RIGHT)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, Ultragenyx Pharmaceutical still faces key risks, including sustained net losses of US$586 million and execution challenges related to its broad rare disease and gene therapy portfolio.
Find out about the key risks to this Ultragenyx Pharmaceutical narrative.
Another View on Ultragenyx Pharmaceutical’s Valuation
That user narrative pins Ultragenyx Pharmaceutical’s fair value close to the current $25.91 share price. Our DCF model comes out very differently. It values the stock at $264.72 based on projected future cash flows, which implies a very large gap that points to serious model risk or potential opportunity. Which set of assumptions do you trust more?
